Esther Zamora - Concepedia

Author

Esther Zamora

Vall d'Hebron Hospital Universitari ORCID

Also Known As

E. Zamora, E. Zamora Adelantado, Ester Zamora, Ester Zamora Adelantado, Esther Zamora, Esther Zamora Adelantado, M Raimunda Vázquez, Mafalda Oliveira

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Vall d'Hebron Hospital Universitari Vall d'Hebron Institute of Oncology Institut Català d'Oncologia Hebron University Institut d'Investigació Biomédica de Bellvitge

About

Esther Zamora is an author at Vall d'Hebron Hospital Universitari specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	338
2	Pathology	3	3	338
3	Cell Biology	2	2	38
4	Immunology	1	1	300
5	Cancer Cell Biology	1	1	19

Esther Zamora

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Clinical Cancer Research	2017	669
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer S. Cedrés, Davis Y. Torrejon, A. Martínez, Clinical & Translational Oncology Cancer ImmunosurveillanceGranulocyteMedicineImmunologyPathology	2012	300
18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial Miguel Quintela-Fandiño, Aňa Lluch, Luís Manso, Clinical Cancer Research	2016	36
Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors Noémie Travier, Genevieve Buckland, Joan Vendrell, European Journal of Cancer Care	2018	31
Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma S. Cedrés, M. A. Montero, Esther Zamora, Clinical & Translational Oncology Tumoral PathologyMalignant Pleural MesotheliomaMalignant DiseaseMedicineCancer Cell Biology	2013	19
Critically short telomeres and toxicity of chemotherapy in early breast cancer Miguel Quintela-Fandiño, Nora Soberón, Aňa Lluch, Oncotarget	2017	19
GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells Chiara Bellio, Marta Emperador, Pol Castellano‐Escuder, Cancers Breast OncologyPathologyDrug TreatmentImmunotherapyCancer Biology	2022	19
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer Tomás Pascual, Juan Miguel Cejalvo, Mafalda Oliveira, Future Oncology	2020	13
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response Nikaoly Ciriaco, Esther Zamora, Santiago Escrivá-de-Romaní, Therapeutic Advances in Medical Oncology	2022	13
Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single‐arm trial Genevieve Buckland, Noémie Travier, Lorena Arribas, Journal of Human Nutrition and Dietetics	2019	11

Page 1